Image

Non Elective Vulnerable Elderly Radiotherapy

Recruiting
70 years of age
Both
Phase N/A

Powered by AI

Overview

To evaluate whether patients defined "non-fit for curative non-surgical radio-chemotherapy" and therefore treated with RT alone addressed only to non-elective sites of disease, could obtain a non-inferior loco-regional control compared to similar historical cohorts.

Description

The current standard approach for head and neck malignancies cannot be considered the gold standard for elderly patients, except in carefully selected cases. Given the relevance of this population, scientific societies also suggest to propose prospective studies for this subset of frail patients (European Organization for Research and treatment of cancer (EORTC), European Society for Medical oncology (ESMO)). In addition, it is necessary to collect data on specific categories, which are as homogeneous as possible. Therefore, the purpose of this study is to evaluate efficacy and safety of a tailored RT approach administered with a curative intent in a subset of frails elderly patients not candidates neither to standard concurrent RT-CT / RT-cetuximab nor to palliative treatment/best supportive care.

Eligibility

Inclusion Criteria:

  • locally advanced non-metastatic HNSCC patients older than 70 years
  • Primary tumor clinically and radiologically detectable and measurable (staging according to ed. TNM VII and also VIII.
  • patients defined by the tumor board (ENT, Oncologist, Radiotherapist, Nutritionist) as
    1. not eligibles for RTCT / RT-cetuximab treatment 2) not amenable to radical surgery and 3) not candidates for treatments with palliative intent/best supportive care
  • Availability of staging with CT/PET for distant metastasis and CT/MRI for primary

    tumor

  • Karnofsky performance status (KPS) ≥60/100
  • Oropharynx , Hypopharynx and Larynx, Oral cavity: stage III and IV and Unknown primitive P16-POSITIVE

Exclusion Criteria:

  • Age less than 70 years
    • Staging exams done 45 days before the date of the beginning of the treatment
    • Subsites: nasopharynx, salivary glands, paranasal sinuses. Metastatic disease
    • Gross total excision
    • All subsites concerned if N3.
    • Squamous cell neoplasms of the glottic larynx T1-T2 N0.
    • Unknown primary HPV negative or EBV positive.
    • Presence of distant metastases or sub-clavicular lymphadenopathies.
    • Previous surgery on T and/or N except diagnostic tonsillectomy.
    • 3D-conformational radiotherapy technique

Study details

Squamous Cell Carcinoma of Head and Neck

NCT04832555

Azienda Ospedaliero Universitaria Policlinico Modena

26 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.